Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mu opioid receptor antagonists: recent developments.

Allan J Goodman1, Bertrand Le Bourdonnec, Roland E Dolle

  • 1Department of Medicinal Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA. agoodman@adolor.com

Chemmedchem
|October 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pathogenic Tau mutation drives autophagy-lysosome dysfunction that limits Tau degradation in a model of frontotemporal dementia.

Nature communications·2026
Same author

Sequelae and reversal of age-dependent alterations in mitochondrial dynamics via autophagy enhancement in reprogrammed human neurons.

bioRxiv : the preprint server for biology·2025
Same author

Targeting hepatocyte-specific SLC2A8 blocks hepatic steatosis and dissociates TCA cycle flux inhibition from glutamine anaplerosis.

Hepatology communications·2025
Same author

Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism.

The Journal of biological chemistry·2025
Same author

Selective inhibition of ERO1α with M6766, a novel small-molecule inhibitor, prevents arterial thrombosis and ischemic stroke in mice.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Pyrimethamine and a potent analogue WCDD115 inhibit NRF2 by suppressing DHFR and one-carbon metabolism.

bioRxiv : the preprint server for biology·2025
Same journal

Investigating the Inhibitory Properties of Diazo and Pyrazole-Carboxamide-Linked Benzenesulfonamides Against Carbonic Anhydrase Isoforms I, II, IX, and XII.

ChemMedChem·2026
Same journal

Quinoxaline-Based Monoamine Oxidase Inhibitors: Design Strategies, Synthesis, Structure-Activity Relationships, and Therapeutic Potential in Neurological Disorders: A Review From 1996 to 2026.

ChemMedChem·2026
Same journal

Immunomodulatory Potential of Quinoline Q3, a Selective Inhibitor of the Canonical NF-κB Pathway in Macrophages.

ChemMedChem·2026
Same journal

Synthesis and Biological Evaluation of C6-O-Glycosylated α-Mangostin Derivatives Against Methicillin-Resistant Staphylococcus aureus With Enhanced Bacterial Membrane Selectivity.

ChemMedChem·2026
Same journal

Piperazine Derivatives Carrying an Imidazole Ring as Selective Modulators of Human Carbonic Anhydrase Isozymes.

ChemMedChem·2026
Same journal

Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment-Based Drug Discovery.

ChemMedChem·2026
See all related articles

Mu opioid antagonists offer pain relief with fewer side effects like dependence. New peripherally restricted compounds show promise for treating various conditions without affecting central pain management.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry

Background:

  • Mu opioid agonists (e.g., morphine) are primary analgesics but cause severe side effects.
  • Current antagonists (naloxone, naltrexone) treat adverse effects but have limitations.

Purpose of the Study:

  • To discuss structural classes of mu opioid antagonists.
  • To explore potential clinical applications beyond current uses.
  • To review recent patents in the field.

Main Methods:

  • Literature review of mu opioid antagonists.
  • Analysis of structural classes and properties.
  • Review of patents filed in the last decade.

Main Results:

  • Identification of various structural classes of mu opioid antagonists.

Related Experiment Videos

  • Exploration of therapeutic potential in pruritus, obesity, and tardive dyskinesia.
  • Highlighting peripherally restricted antagonists (N-methylnaltrexone, alvimopan) for targeted side effect management.

    • Conclusions:

    • Mu opioid receptor antagonism has broad therapeutic potential.
    • Peripherally restricted antagonists offer a promising approach to manage opioid-induced side effects without compromising analgesia.
    • Ongoing research and patent activity indicate a dynamic field.